Compare WGRX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WGRX | NEUP |
|---|---|---|
| Founded | 2022 | 1996 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Other Pharmaceuticals | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 23.0M |
| IPO Year | N/A | N/A |
| Metric | WGRX | NEUP |
|---|---|---|
| Price | $0.24 | $4.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | ★ 783.9K | 22.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $3.65 |
| 52 Week High | $7.04 | $21.31 |
| Indicator | WGRX | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 29.20 | 61.86 |
| Support Level | N/A | $3.99 |
| Resistance Level | $0.45 | $4.43 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 18.04 | 82.16 |
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.